BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34680117)

  • 1. Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies.
    Campo MD; Pijnenburg YAL; Chen-Plotkin A; Irwin DJ; Grossman M; Twaalfhoven HAM; Hu WT; Meeter LH; van Swieten J; Vermunt L; Martens F; Heijboer AC; Teunissen CE
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.
    Kuiperij HB; Versleijen AA; Beenes M; Verwey NA; Benussi L; Paterlini A; Binetti G; Teunissen CE; Raaphorst J; Schelhaas HJ; Küsters B; Pijnenburg YA; Ghidoni R; Verbeek MM
    J Alzheimers Dis; 2017; 55(2):585-595. PubMed ID: 27662293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.
    Cervantes González A; Irwin DJ; Alcolea D; McMillan CT; Chen-Plotkin A; Wolk D; Sirisi S; Dols-Icardo O; Querol-Vilaseca M; Illán-Gala I; Santos-Santos MA; Fortea J; Lee EB; Trojanowski JQ; Grossman M; Lleó A; Belbin O
    Mol Neurodegener; 2022 Apr; 17(1):29. PubMed ID: 35395770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CSF biomarkers for frontotemporal lobar degenerations.
    Hu WT; Chen-Plotkin A; Grossman M; Arnold SE; Clark CM; Shaw LM; McCluskey L; Elman L; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Neurology; 2010 Dec; 75(23):2079-86. PubMed ID: 21048198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid.
    Hok-A-Hin YS; Dijkstra AA; Rábano A; Hoozemans JJ; Castillo L; Seelaar H; van Swieten JC; Pijnenburg YAL; Teunissen CE; Del Campo M
    Neurobiol Dis; 2022 Oct; 172():105813. PubMed ID: 35820647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
    Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes.
    Del Campo M; Galimberti D; Elias N; Boonkamp L; Pijnenburg YA; van Swieten JC; Watts K; Paciotti S; Beccari T; Hu W; Teunissen CE
    Ann Clin Transl Neurol; 2018 Oct; 5(10):1163-1175. PubMed ID: 30349851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP.
    Hu WT; Watts K; Grossman M; Glass J; Lah JJ; Hales C; Shelnutt M; Van Deerlin V; Trojanowski JQ; Levey AI
    Neurology; 2013 Nov; 81(22):1945-52. PubMed ID: 24174584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.
    Goossens J; Bjerke M; Van Mossevelde S; Van den Bossche T; Goeman J; De Vil B; Sieben A; Martin JJ; Cras P; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2018 Mar; 10(1):31. PubMed ID: 29559004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum.
    Ohm DT; Peterson C; Lobrovich R; Cousins KAQ; Gibbons GS; McMillan CT; Wolk DA; Van Deerlin V; Elman L; Spindler M; Deik A; Siderowf A; Trojanowski JQ; Lee EB; Grossman M; Irwin DJ
    Acta Neuropathol; 2020 Nov; 140(5):675-693. PubMed ID: 32804255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia.
    Borroni B; Benussi A; Archetti S; Galimberti D; Parnetti L; Nacmias B; Sorbi S; Scarpini E; Padovani A
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):86-91. PubMed ID: 25352065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes.
    Pijnenburg YA; Verwey NA; van der Flier WM; Scheltens P; Teunissen CE
    Alzheimers Dement (Amst); 2015 Dec; 1(4):505-12. PubMed ID: 27239528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series.
    Kim EJ; Brown JA; Deng J; Hwang JL; Spina S; Miller ZA; DeMay MG; Valcour V; Karydas A; Ramos EM; Coppola G; Miller BL; Rosen HJ; Seeley WW; Grinberg LT
    J Neurol; 2018 Dec; 265(12):2960-2971. PubMed ID: 30324308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
    Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
    Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology.
    Tisdall MD; Ohm DT; Lobrovich R; Das SR; Mizsei G; Prabhakaran K; Ittyerah R; Lim S; McMillan CT; Wolk DA; Gee J; Trojanowski JQ; Lee EB; Detre JA; Yushkevich P; Grossman M; Irwin DJ
    Neuroimage Clin; 2022; 33():102913. PubMed ID: 34952351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.